711 (Mesalamine Delayed-Release 1.2 g)
Pill with imprint 711 is Brown, Elliptical/Oval and has been identified as Mesalamine Delayed-Release 1.2 g. It is supplied by Zydus Pharmaceuticals (USA) Inc.
Mesalamine is used in the treatment of crohn's disease, maintenance; inflammatory bowel disease; ulcerative colitis, maintenance; ulcerative colitis; ulcerative proctitis and belongs to the drug class 5-aminosalicylates. excluding Asacol and Asacol HD: There is no proven risk in humans during pregnancy. Asacol and Asacol HD: Risk cannot be ruled out during pregnancy. Mesalamine 1.2 g is not a controlled substance under the Controlled Substances Act (CSA).
Images for 711
Mesalamine Delayed-Release
- Imprint
- 711
- Strength
- 1.2 g
- Color
- Brown
- Size
- 10.00 mm
- Shape
- Elliptical/Oval
- Availability
- Prescription only
- Drug Class
- 5-aminosalicylates
- Pregnancy Category
- B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Zydus Pharmaceuticals (USA) Inc.
- National Drug Code (NDC)
- 68382-0711
- Inactive Ingredients
-
carboxymethylcellulose sodium,
microcrystalline cellulose,
ferric oxide red,
ferric oxide yellow,
hypromelloses,
magnesium stearate,
methacrylic acid,
silicon dioxide,
sodium starch glycolate type A potato,
magnesium silicate,
titanium dioxide,
triethyl citrate
Note: Inactive ingredients may vary.
Related images for "711"
More about mesalamine
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (382)
- Drug images
- Compare alternatives
- Pricing & coupons
- Drug class: 5-aminosalicylates
Patient resources
- Drug Information
- Mesalamine rectal
- Mesalamine (Advanced Reading)
- Mesalamine Rectal (Advanced Reading)
- Mesalamine Tablets
Other brands
Pentasa, Lialda, Asacol, Apriso, ... +7 more
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.